On October 16, 2026, Alector, a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, announced the pricing of an underwritten offering of common stock. Alector is selling 36,600,000 shares of common stock at an offering price of $2.05 per share, which represents a premium of approximately 7.3 percent over the closing price on October 15, 2026. The gross proceeds to Alector from this offering are expected to be $75,030,000 before deducting the underwriting discounts and commissions and other estimated offering expenses. The financing includes participation from new and existing investors, including TCGX, BVF Partners, ADAR1 Capital Management, and Deep Track Capital, among others. Wilson Sonsini Goodrich & Rosati advised Alector on the transaction.

The Wilson Sonsini team that advised Alector on the transaction includes:

Corporate
Ken Clark
Michael Coke
Christina Poulsen
Enid Qin
Zach Shen
Riven Bu

Tax
Myra Sutanto Shen
Anjali Krishnan

Technology Transactions
Matt Wiltermuth
Colin Bosch

Fintech and Financial Services
Michael McDonald
Alice Cao

FDA Regulatory
Eva Yin

For more information, please see Alector’s news release.